



HyperUricemia

UNDER CONTROL



HYPERURICEMIA¹⁻⁶

American College of Rheumatology
(ACR) definition of hyperuricemia²



Serum urate greater than either
6.8 or 7.0 mg/dL²

Clinical phenotypes of hyperuricemia^{1,3}



Prevalence of hyperuricemia^{1,3}



Association of asymptomatic hyperuricemia with chronic diseases⁵

01

Even after understanding the delirious effects of elevated serum uric acid levels – other than gouty arthritis; measuring serum uric acid is not a routine general practice.

02

Hence, hyperuricemia may often go undiagnosed.

03

Undiagnosed and **asymptomatic hyperuricemia pose several health risks**, beyond gout and nephrolithiasis.

Prevalence of hyperuricemia in different disease states⁶



Type 2 diabetes:
25.35%



Metabolic syndrome:
47.1%



Obesity:
44.6%



Hypertension:
37.33%

European Guidelines have therefore officially introduced uric acid evaluation among the risk factors that should be evaluated in order to stratify a patient's cardiovascular risk.⁷

TREATMENT OF ASYMPTOMATIC HYPERURICEMIA


Target level

- Target for serum uric acid for patients on therapy for asymptomatic hyperuricemia is **<6 mg/dl**.⁸

Dose titration of febuxostat in asymptomatic hyperuricemia⁸

- Febuxostat is a first-line agent since it is metabolised by the hepatic route and has renal benefits.
- Starting dose for Febuxostat is 40 mg/day, which can be titrated gradually in order to achieve the target. Long-term (one-year) maintenance dose, 20 mg daily.^{8,9}

Algorithm for initiation, management, and maintenance of hyperuricemia with febuxostat¹⁰



URATE LOWERING THERAPY & EFFECT ON HYPERTENSION (BLOOD PRESSURE)

A recent systematic review and network meta-analysis compared intervention group (patients receiving urate-lowering drugs; allopurinol, febuxostat, and benzbromarone) with others using other types of drugs, placebo, or usual care, and showed following **long-term effect**:¹¹



No significant difference of systolic/diastolic BP was found between groups in long-term; except **patients in febuxostat group had 1.47 mmHg statistically lower diastolic BP** than patients in placebo group.¹¹

In patients with asymptomatic hyperuricemia, urate-lowering therapy does not result in a higher risk of safety events.¹¹

References: 1. George C, Minter DA. Hyperuricemia. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK459218/> [Accessed on: 7-7-2022] 2. Khanna D, FitzGerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Non-pharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. *Arthritis Care Res (Hoboken)*. 2012;64(10):1431-1446. 3. Mount DB, Dalbeth N, Romain PL. Asymptomatic hyperuricemia. Available at: <https://www.uptodate.com/contents/asymptomatic-hyperuricemia#:~:text=Asymptomatic%20hyperuricemia%20is%20a%20term,acid%20renal%20disease%2C%20have%20occurred.> [Accessed on: 7-7-2022] 4. Joosten LAB, Crijan TO, Bjornstad P, et al. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. *Nat Rev Rheumatol*. 2020;16(2):75-86. 5. Raja S, Kumar A, Aahooja RD, et al. Frequency of Hyperuricemia and its Risk Factors in the Adult Population. *Cureus*. 2019;11(3):e4198. 6. Patel H, Shah D. Hyperuricemia prevalence in Indian subjects with underlying comorbidities of hypertension and/or type 2 diabetes: a retrospective study from subjects attending hyperuricemia screening camps. *Int J Res Med Sci*. 2020;8(3):794-800. 7. Maloberti A, Giannattasio C, Bombelli M, et al. Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. *High Blood Press Cardiovasc Prev*. 2020;27(2):121-128. 8. Valsaraj R, Singh AK, Gangopadhyay KK, et al. Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. *Diabetes Metab Syndr*. 2020;14(2):93-100. 9. Sofue T, Inui M, Hara T, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. *Drug Des Devel Ther*. 2014;8:245-253. 10. Ray DS, Nair T, Dargad R, Dhar V. A Review of Hyperuricaemia Management with Febuxostat: Dosage Titration, Monitoring and Maintenance. *Journal of Clinical and Diagnostic Research*. 2022;16(1):OE07-OE14. 11. Tien YY, Shih MC, Tien CP, et al. To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis. *J Am Board Fam Med* 2022;35:140-151.



Febustat

Febuxostat 20 mg / 40 mg / 80 mg Tablets

Stay in control, always

Disclaimer: The scientific content of this publication has been developed and designed by Passi Healthcom Pvt. Ltd. for educational purpose through monetary assistance of Abbott Healthcare Private Limited and is intended to be purely an educational update. This publication is distributed free of cost as a service to the medical profession for educational purpose only. Medical practitioners are advised to take decisions based on their own clinical judgment. The content herein has been developed by clinicians and/or medical writers and/or experts. Although greatest possible care has been taken in compiling, checking and developing the content to ensure that it is accurate and complete, the authors, the publisher, its servants or agents, or Abbott Healthcare Pvt. Ltd., are not responsible or in any way liable for any injury or damage to any persons in view of any reliance placed on or action taken basis of the information in this publication or any errors, omissions or inaccuracies and/or incompleteness of the information in this publication, whether arising from negligence or otherwise. The content of this publication constitutes solely the views of its authors. Abbott Healthcare Pvt. Ltd. neither agrees nor disagrees with the views expressed in this publication and does not constitute or imply an endorsement, sponsorship or recommendation of any kind. As the information contained herein is for educational purpose only we request you to please refer to the full prescribing information for complete details of any products.